Drug Profile
Research programme: coronavirus hybrid vaccines - NuGenerex Immuno-Oncology
Alternative Names: 2019-nCOV hybrid vaccines - NuGenerex Immuno-Oncology; 2019-nCOV specific Li-Key-hybrids vaccinesLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator NuGenerex Immuno-Oncology
- Class COVID-19 vaccines; Peptide vaccines; Synthetic vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 06 Feb 2020 Coronavirus hybrid vaccines - NuGenerex Immuno-Oncology is available for licensing as of 06 Feb 2020. www.generex.com
- 06 Feb 2020 Early research in COVID-2019-infections (Prevention) in USA (Parenteral)